Synthetic Biologics, Inc. (SYN)
SYNPrice: $1.02
Fair Value: 🔒
🔒score
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the pr... more
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in area... more
Description
Shares
| Market Cap | $16.16M | Exchange | AMEX |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Steven Shallcross |
| IPO Date | 1993-02-12 | CAGR | — |
| Employees | 16 | Website | www.syntheticbiologics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SYN chart loading...
Fundamentals
Technicals
| Enterprise Value | $-3.98M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 17.27 | P/B Ratio | 0.18 |
| P/CF Ratio | -0.1 | P/FCF Ratio | -0.15 |
| EPS | $-0.12 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | -0.06% |
| Operating Margin | -135.47% | Profit Margin | -191.92% |
| ROE | -1.69% | ROA | -0.82% |
| ROCE | -0.89% | Current Ratio | 1.19 |
| Quick Ratio | 1.19 | Cash Ratio | 0.98 |
| Debt/Equity | 0.12 | Interest Coverage | — |
| Altman Z Score | -16.77 | Piotroski Score | 3 |